Drivers Medtronic Others

1. Drivers Medtronic Others Phone Number
2. Drivers Medtronic Others Online
3. Drivers Medtronic Others Inc

1. Support Overview. MiniMed™ 770G System. MiniMed™ 670G System. MiniMed™ 630G System. MiniMed™ 530G System. Guardian™ Connect System. CareLink™ Software.
2. Medtronic's original ethos of helping patients further together is, and remains, the primary driver. This is set out clearly in the company's mission statement: 'Through a process of ongoing innovation and collaboration, Medtronic helps to alleviate pain, restore health and extend patient life.'.

With an attitude for innovation, collaboration and cross-fertilization, Medtronic has been a leader in medical technology (MedTech) in the Netherlands for the last 50 years. Taking root in the fertile ground of the Netherlands, Medtronic has been the driver of innovative research collaborations, which are taking health care further, together, to the future.

Leader in medical technology

Founded in the USA, in 1949, as a medical equipment repair company, Medtronic has grown to become one of the largest medical technology companies in the world. Over many years, the company has developed its core technologies, including implantable mechanical devices, drug and biologic delivery devices, and powered and advanced energy surgical instruments. Through a process of ongoing innovation and collaboration, Medtronic helps to alleviate pain, restore health and extend patient life. In 2018, Medtronic's medical therapies for the treatment of over 70 major conditions, helped improve the lives of more than 71 million people around the world – equivalent to two people every second.

Acquisition Will Accelerate Medtronic's Strategy to Provide AI and Data Within Laparoscopic and Robotic Assisted Surgery. 13, 2020 (GLOBE NEWSWIRE) - Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the acquisition of Digital Surgery, a privately-held pioneer in surgical artificial intelligence (AI), data and analytics, and digital education. ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office. Lead to stent embolization. The Medtronic Driver Rapid Exchange Coronary Stent System is intended to perform as a system. The Medtronic Driver Stent is not designed to be crimped onto another delivery device. Stent Delivery System should not be used in conjunction with any other stents.

Medtronic has had a presence in the province of Limburg, in the south of the Netherlands, since 1969 and is this year celebrating its 50^th anniversary. Today, all of Medtronic's therapy groups and divisions are represented here, and the company employs around 3,000 people, including contractors, throughout the Netherlands.

Location. Logistics. Loquacity.

When, in 1969, Medtronic co-founder Earl Bakken was looking for a location for the first facility outside of US, he came to the Netherlands and opted for South-Limburg because of its centralized location and the rapid and easy connections with the rest of Europe. Key considerations, both then and now, included direct access to excellent road, rail and air infrastructure. Additionally, the proximity of the major sea harbors of Rotterdam and Antwerp, combined with the very close proximity to air hubs of major global transport integrators, made South Limburg the ideal location to establish operations. Sikko Zoer – VP Customer Care and Supply Chain, EMEA: 'Medtronic the Netherlands is located mostly in Limburg. This province is called ‘the balcony of Europe', which accounts for the international mindset of the inhabitants (the Limburgers). The ample availability of a well-trained labor force with the necessary language skills contributed significantly to Medtronic's global growth from Limburg'.

Collaborative LSH ecosystem

In 1987, Medtronic founded the Bakken Research Center (BRC) in Maastricht with 45 employees. Today, that number has grown to more than 400 international talents from 35 different nationalities. BRC is unique due to the multiple specialties and expertise concentrated at one location – which stimulates cross-fertilization and collaboration. Multiple Business Units work together at Medtronic BRC, enabling the sharing of knowledge and best practices. Melec USB devices Driver download. Leo Kretzers – Vice President and General Manager of the Medtronic Bakken Research Center: 'We are unique, as we have a leading role in driving access to Medtronic therapies, from idea to market adoption'. BRC is one of the largest Medtronic R&D campuses outside the United States. BRC's many international experts and scientists work closely with Dutch knowledge institutes such as Maastricht University, the University Academic Hospital and the multiple innovation campuses at Brightlands. In recent years, BRC has been at the forefront of key medical device innovations such as dual-chamber pacemakers, sacral neuromodulation, cardiac resynchronization therapy and deep brain stimulation. The Bakken Research Center excels in therapy innovation, clinical and economic evidence, regulatory approval and translations.

Drivers Medtronic Others Phone Number

Sustaining focus

Medtronic is an active participant in regional educational initiatives, with direct connections to regional educational institutes for middle- and higher education. A prime example is the in-house training for Logistics operator that has been developed in close collaboration with colleagues/regional MedTech companies, training institutes, the Province of Limburg and the municipalities in the region. This collaboration led to the establishment of the successful ‘Beyond' project – a unique medical device and medical supply chain community. The project aims to attract potential employees ‘with a distance to the labor market' and offer them in-company training on the job and in-house education, ultimately resulting in an official MBO certificate for Logistics operator. In this way, in parallel to its mission to improve patient lives, Medtronic is helping to ensure the future of young people in the region and contributing to the local Dutch life sciences and health ecosystem.

Together, to the future

Medtronic's original ethos of helping patients further together is, and remains, the primary driver. This is set out clearly in the company's mission statement: 'Through a process of ongoing innovation and collaboration, Medtronic helps to alleviate pain, restore health and extend patient life.' Medtronic is continuously looking for new ways to ensure that its efforts are impactful and well-executed, and this cannot be achieved in isolation. Today, collaboration is an essential part of its modern ecosystem for innovation. Consequently, Medtronic collaborates intensively with academia, industry, society and governments, referred to as the Quadruple Helix approach. This collaboration ultimately contributes to the further development of medical technology and the improvement of patient and economic outcomes, taking healthcare further.

Indications, Safety & Warnings

Intended Use

The Medtronic Driver Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo or restenotic lesions with reference vessel diameters of 3.0 mm to 4.0 mm and ≤30 mm in length using direct stenting or predilatation.

Contraindications

Drivers Medtronic Others Online

• Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated.
• Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.

Warnings/Precautions

• Judicious selection of patients is necessary since the use of this device carries the associated risk of subacute thrombosis, vascular complications and/or bleeding events. Administration of appropriate anticoagulant, antiplatelet and coronary vasodilator therapy is critical to successful stent implantation and follow-up.
• Patients allergic to F-562 cobalt-chromium alloy may suffer an allergic reaction to this implant.
• Only physicians who have received appropriate training should perform implantation of the stent.
• Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed.
• Subsequent restenosis may require repeat dilatation of the arterial segment containing the stent. The long-term outcome following repeat dilatation of endothelialized coronary stents is unknown at present.
• When multiple stents are required, stent materials should be of similar composition. Placing multiple stents of different materials in contact with each other may increase the potential for corrosion. Data obtained from in vitro corrosion tests using a F562 CoCr alloy stent (Medtronic Driver Coronary Stent) in combination with a 316L stainless steel alloy stent (Medtronic S7 Coronary Stent) do not suggest an increased risk of in vivo corrosion.
• If the physician encounters difficulty while trying to cross the lesion by direct stenting and determines the lesion to be uncrossable, this patient should be treated per predilatation practice. The stent (the same stent if undamaged) or a new stent of the same kind should then be advanced and deployed with predilatation.
• Implanting a stent may lead to dissection of the vessel distal and/or proximal to the stented portion and may cause acute closure of the vessel requiring additional intervention (e.g., CABG, further dilatation, placement of additional stents or other).
• Outcomes (beyond 270 days) for this permanent implant are unknown at present.

Adverse Events

Potential adverse events that may be associated with the use of a coronary stent in native coronary arteries (including those listed in the Driver Instructions for Use) are death, myocardial infarction, emergency coronary artery bypass graft surgery (CABG), stent thrombosis, bleeding complications, stroke/cerebrovascular accidents, vascular complications, stent failures, acute myocardial infarction, myocardial ischemia, arrhythmias (including ventricular fibrillation and ventricular tachycardia dissection), distal emboli (air, tissue or thrombotic emboli), hemorrhage requiring transfusion, perforation, restenosis of stented segments, stent embolization, total occlusion of coronary artery, cardiac tamponade, femoral pseudoaneurysm, spasm, hypotension/ hypertension, allergic reaction to drugs/contrast medium/stent material, peripheral ischemia, peripheral nerve injury, infection and pain at the insertion site, and hematoma.

Please reference appropriate product Instructions for Use for a more detailed list of indications, warnings, precautions and potential adverse events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. Drivers king young.

Drivers Medtronic Others Inc

Micro-Driver^® Coronary Stent Systems

Intended Use

The Medtronic Micro-Driver Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions with reference vessel diameters of 2.25–2.75 mm and ≤21 mm in length. Outcome beyond 270 days for this permanent implant is unknown at present.

Contraindications

1. Support Overview. MiniMed™ 770G System. MiniMed™ 670G System. MiniMed™ 630G System. MiniMed™ 530G System. Guardian™ Connect System. CareLink™ Software.
2. Medtronic's original ethos of helping patients further together is, and remains, the primary driver. This is set out clearly in the company's mission statement: 'Through a process of ongoing innovation and collaboration, Medtronic helps to alleviate pain, restore health and extend patient life.'.

With an attitude for innovation, collaboration and cross-fertilization, Medtronic has been a leader in medical technology (MedTech) in the Netherlands for the last 50 years. Taking root in the fertile ground of the Netherlands, Medtronic has been the driver of innovative research collaborations, which are taking health care further, together, to the future.

Leader in medical technology

Founded in the USA, in 1949, as a medical equipment repair company, Medtronic has grown to become one of the largest medical technology companies in the world. Over many years, the company has developed its core technologies, including implantable mechanical devices, drug and biologic delivery devices, and powered and advanced energy surgical instruments. Through a process of ongoing innovation and collaboration, Medtronic helps to alleviate pain, restore health and extend patient life. In 2018, Medtronic's medical therapies for the treatment of over 70 major conditions, helped improve the lives of more than 71 million people around the world – equivalent to two people every second.

Acquisition Will Accelerate Medtronic's Strategy to Provide AI and Data Within Laparoscopic and Robotic Assisted Surgery. 13, 2020 (GLOBE NEWSWIRE) - Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the acquisition of Digital Surgery, a privately-held pioneer in surgical artificial intelligence (AI), data and analytics, and digital education. ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office. Lead to stent embolization. The Medtronic Driver Rapid Exchange Coronary Stent System is intended to perform as a system. The Medtronic Driver Stent is not designed to be crimped onto another delivery device. Stent Delivery System should not be used in conjunction with any other stents.

Medtronic has had a presence in the province of Limburg, in the south of the Netherlands, since 1969 and is this year celebrating its 50^th anniversary. Today, all of Medtronic's therapy groups and divisions are represented here, and the company employs around 3,000 people, including contractors, throughout the Netherlands.

Location. Logistics. Loquacity.

When, in 1969, Medtronic co-founder Earl Bakken was looking for a location for the first facility outside of US, he came to the Netherlands and opted for South-Limburg because of its centralized location and the rapid and easy connections with the rest of Europe. Key considerations, both then and now, included direct access to excellent road, rail and air infrastructure. Additionally, the proximity of the major sea harbors of Rotterdam and Antwerp, combined with the very close proximity to air hubs of major global transport integrators, made South Limburg the ideal location to establish operations. Sikko Zoer – VP Customer Care and Supply Chain, EMEA: 'Medtronic the Netherlands is located mostly in Limburg. This province is called ‘the balcony of Europe', which accounts for the international mindset of the inhabitants (the Limburgers). The ample availability of a well-trained labor force with the necessary language skills contributed significantly to Medtronic's global growth from Limburg'.

Collaborative LSH ecosystem

In 1987, Medtronic founded the Bakken Research Center (BRC) in Maastricht with 45 employees. Today, that number has grown to more than 400 international talents from 35 different nationalities. BRC is unique due to the multiple specialties and expertise concentrated at one location – which stimulates cross-fertilization and collaboration. Multiple Business Units work together at Medtronic BRC, enabling the sharing of knowledge and best practices. Melec USB devices Driver download. Leo Kretzers – Vice President and General Manager of the Medtronic Bakken Research Center: 'We are unique, as we have a leading role in driving access to Medtronic therapies, from idea to market adoption'. BRC is one of the largest Medtronic R&D campuses outside the United States. BRC's many international experts and scientists work closely with Dutch knowledge institutes such as Maastricht University, the University Academic Hospital and the multiple innovation campuses at Brightlands. In recent years, BRC has been at the forefront of key medical device innovations such as dual-chamber pacemakers, sacral neuromodulation, cardiac resynchronization therapy and deep brain stimulation. The Bakken Research Center excels in therapy innovation, clinical and economic evidence, regulatory approval and translations.

Drivers Medtronic Others Phone Number

Sustaining focus

Medtronic is an active participant in regional educational initiatives, with direct connections to regional educational institutes for middle- and higher education. A prime example is the in-house training for Logistics operator that has been developed in close collaboration with colleagues/regional MedTech companies, training institutes, the Province of Limburg and the municipalities in the region. This collaboration led to the establishment of the successful ‘Beyond' project – a unique medical device and medical supply chain community. The project aims to attract potential employees ‘with a distance to the labor market' and offer them in-company training on the job and in-house education, ultimately resulting in an official MBO certificate for Logistics operator. In this way, in parallel to its mission to improve patient lives, Medtronic is helping to ensure the future of young people in the region and contributing to the local Dutch life sciences and health ecosystem.

Together, to the future

Medtronic's original ethos of helping patients further together is, and remains, the primary driver. This is set out clearly in the company's mission statement: 'Through a process of ongoing innovation and collaboration, Medtronic helps to alleviate pain, restore health and extend patient life.' Medtronic is continuously looking for new ways to ensure that its efforts are impactful and well-executed, and this cannot be achieved in isolation. Today, collaboration is an essential part of its modern ecosystem for innovation. Consequently, Medtronic collaborates intensively with academia, industry, society and governments, referred to as the Quadruple Helix approach. This collaboration ultimately contributes to the further development of medical technology and the improvement of patient and economic outcomes, taking healthcare further.

Indications, Safety & Warnings

Intended Use

The Medtronic Driver Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo or restenotic lesions with reference vessel diameters of 3.0 mm to 4.0 mm and ≤30 mm in length using direct stenting or predilatation.

Contraindications

Drivers Medtronic Others Online

• Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated.
• Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.

Warnings/Precautions

• Judicious selection of patients is necessary since the use of this device carries the associated risk of subacute thrombosis, vascular complications and/or bleeding events. Administration of appropriate anticoagulant, antiplatelet and coronary vasodilator therapy is critical to successful stent implantation and follow-up.
• Patients allergic to F-562 cobalt-chromium alloy may suffer an allergic reaction to this implant.
• Only physicians who have received appropriate training should perform implantation of the stent.
• Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed.
• Subsequent restenosis may require repeat dilatation of the arterial segment containing the stent. The long-term outcome following repeat dilatation of endothelialized coronary stents is unknown at present.
• When multiple stents are required, stent materials should be of similar composition. Placing multiple stents of different materials in contact with each other may increase the potential for corrosion. Data obtained from in vitro corrosion tests using a F562 CoCr alloy stent (Medtronic Driver Coronary Stent) in combination with a 316L stainless steel alloy stent (Medtronic S7 Coronary Stent) do not suggest an increased risk of in vivo corrosion.
• If the physician encounters difficulty while trying to cross the lesion by direct stenting and determines the lesion to be uncrossable, this patient should be treated per predilatation practice. The stent (the same stent if undamaged) or a new stent of the same kind should then be advanced and deployed with predilatation.
• Implanting a stent may lead to dissection of the vessel distal and/or proximal to the stented portion and may cause acute closure of the vessel requiring additional intervention (e.g., CABG, further dilatation, placement of additional stents or other).
• Outcomes (beyond 270 days) for this permanent implant are unknown at present.

Adverse Events

Potential adverse events that may be associated with the use of a coronary stent in native coronary arteries (including those listed in the Driver Instructions for Use) are death, myocardial infarction, emergency coronary artery bypass graft surgery (CABG), stent thrombosis, bleeding complications, stroke/cerebrovascular accidents, vascular complications, stent failures, acute myocardial infarction, myocardial ischemia, arrhythmias (including ventricular fibrillation and ventricular tachycardia dissection), distal emboli (air, tissue or thrombotic emboli), hemorrhage requiring transfusion, perforation, restenosis of stented segments, stent embolization, total occlusion of coronary artery, cardiac tamponade, femoral pseudoaneurysm, spasm, hypotension/ hypertension, allergic reaction to drugs/contrast medium/stent material, peripheral ischemia, peripheral nerve injury, infection and pain at the insertion site, and hematoma.

Please reference appropriate product Instructions for Use for a more detailed list of indications, warnings, precautions and potential adverse events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. Drivers king young.

Drivers Medtronic Others Inc

Micro-Driver^® Coronary Stent Systems

Intended Use

The Medtronic Micro-Driver Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions with reference vessel diameters of 2.25–2.75 mm and ≤21 mm in length. Outcome beyond 270 days for this permanent implant is unknown at present.

Contraindications

• Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated.
• Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.

Warnings/Precautions

• Judicious selection of patients is necessary since the use of this device carries the associated risk of subacute thrombosis, vascular complications and/or bleeding events. Administration of appropriate anticoagulant, antiplatelet and coronary vasodilator therapy is critical to successful stent implantation and follow-up.
• Patients allergic to F-562 cobalt-chromium alloy (alloy components include cobalt, chromium, or nickel) may suffer an allergic reaction to this implant.
• Only physicians who have received appropriate training should perform implantation of the stent.
• Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed.
• Subsequent restenosis may require repeat dilatation of the arterial segment containing the stent. The long-term outcome following repeat dilatation of endothelialized coronary stents is unknown at present.
• When multiple stents are required, stent materials should be of similar composition. Placing multiple stents of different materials in contact with each other may increase the potential for corrosion. Data obtained from in vitro corrosion tests using a F562 CoCr alloy stent (Medtronic Driver Coronary Stent) in combination with a 316L stainless steel alloy stent (Medtronic S7 Coronary Stent) do not suggest an increased risk of in vivo corrosion.

Adverse Events

Potential adverse events that may be associated with the use of a coronary stent in native coronary arteries in order of severity are death, emergency Coronary Artery Bypass Graft Surgery (CABG), stroke/cerebrovascular accidents, cardiac tamponade, stent thrombosis or occlusion, total occlusion of coronary artery, acute myocardial infarction, restenosis of stented segments, perforation, arrhythmias (including ventricular fibrillation and ventricular tachycardia), dissection, distal emboli (air, tissue or thrombotic emboli), stent embolization, hemorrhage requiring transfusion, femoral pseudoaneurysm, spasm , myocardial ischemia, hypotension/hypertension, allergic reaction to drugs/contrast medium/stent material, peripheral ischemia, peripheral nerve injury, infection and pain at the insertion site, and hematoma.

Please reference appropriate product Instructions for Use for a more detailed list of indications, warnings, precautions and potential adverse events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.